On August 24, WUXI XDC declined 3.28% in regular trading, trading at 69.25 HKD/share, with turnover of approximately 75.77 million HKD.

On the news front, the company is scheduled to hold a board meeting on the same day to review and approve its interim results for the six months ended June 30. The stock had previously rallied on multiple catalysts — including the successful GMP approval of its Singapore-based BCM3 dual-function production line and strong interim results expectations — creating short-term profit-taking pressure. The Singapore BCM3 milestone, announced on August 18, drove the stock up over 8% in a single session, while further gains of over 4% followed on August 20.

The broader Life Sciences Tools and Services sector is under broad selling pressure, with GENSCRIPT BIO down 3.72%, WUXI BIO down 2.86%, and WUXI APPTEC down 1.94%. Multiple brokerages including CLSA and Daiwa maintain bullish ratings on the company, with target prices of 82.6 HKD and 78 HKD respectively, citing strong ADC outsourcing market share gains and robust revenue growth forecasts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)